Shares of GALAPAGOS NV/S (NASDAQ:GLPG) have received an average rating of “Buy” from the sixteen brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $177.57.
Several equities analysts have weighed in on the company. Credit Suisse Group reaffirmed an “outperform” rating on shares of GALAPAGOS NV/S in a research note on Wednesday, July 10th. Cowen reaffirmed a “buy” rating on shares of GALAPAGOS NV/S in a research note on Friday, July 26th. Nomura lifted their target price on GALAPAGOS NV/S from $140.00 to $209.00 and gave the company a “buy” rating in a research note on Monday, July 29th. BidaskClub cut GALAPAGOS NV/S from a “hold” rating to a “sell” rating in a research note on Thursday, October 3rd. Finally, Raymond James cut GALAPAGOS NV/S from a “strong-buy” rating to a “market perform” rating in a research note on Monday, July 15th.
NASDAQ:GLPG traded up $3.78 on Wednesday, hitting $155.23. 2,454 shares of the company’s stock traded hands, compared to its average volume of 129,318. The company has a current ratio of 6.40, a quick ratio of 6.40 and a debt-to-equity ratio of 0.02. GALAPAGOS NV/S has a 1 year low of $85.00 and a 1 year high of $191.63. The firm has a 50-day moving average price of $160.28 and a 200-day moving average price of $139.69. The company has a market cap of $8.32 billion, a PE ratio of -235.02 and a beta of 1.55.
GALAPAGOS NV/S (NASDAQ:GLPG) last released its earnings results on Thursday, July 25th. The biotechnology company reported ($0.97) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.13). GALAPAGOS NV/S had a negative net margin of 19.95% and a negative return on equity of 5.45%. The business had revenue of $75.96 million for the quarter, compared to analysts’ expectations of $56.66 million. On average, research analysts forecast that GALAPAGOS NV/S will post 5.17 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in GLPG. Royal Bank of Canada increased its position in shares of GALAPAGOS NV/S by 206.1% during the second quarter. Royal Bank of Canada now owns 251 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 169 shares during the period. Ladenburg Thalmann Financial Services Inc. bought a new stake in shares of GALAPAGOS NV/S during the second quarter valued at approximately $59,000. OneAscent Financial Services LLC bought a new stake in shares of GALAPAGOS NV/S during the second quarter valued at approximately $342,000. Victory Capital Management Inc. increased its position in shares of GALAPAGOS NV/S by 35.0% during the second quarter. Victory Capital Management Inc. now owns 32,826 shares of the biotechnology company’s stock valued at $4,232,000 after purchasing an additional 8,510 shares during the period. Finally, UBS Asset Management Americas Inc. increased its position in shares of GALAPAGOS NV/S by 19.1% during the second quarter. UBS Asset Management Americas Inc. now owns 14,540 shares of the biotechnology company’s stock valued at $1,875,000 after purchasing an additional 2,327 shares during the period. 15.58% of the stock is owned by institutional investors and hedge funds.
About GALAPAGOS NV/S
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Further Reading: Are FAANG stocks a good investment?
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.